Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations.
A new delivery system, Ionic Amphiphilic Biovector (ABV), comprised of anionic lipids (dipalmitoyl phosphatidyl glycerol) included in a cationic cross-linked polysaccharide matrix was used as a reservoir for amphotericin B (AmB). Two ABV formulations exhibited an in vitro and in vivo efficacy similar to commercial AmBisome against Leishmania donovani-infected mice. The higher stability of these ABV formulations indicates their potential for further development and applications.
Loiseau
P M
PM
LBCOP, UPRES 398-IFR 75, Faculté de Pharmacie, Université de Paris XI, 92290 Chatenay-Malabry Cedex, France. philippe.loiseau@cep.u-psud.fr
Imbertie
L
L
Bories
C
C
Betbeder
D
D
De Miguel
I
I
D000666:Amphotericin B / Q000008:administration & dosage* / Q000627:therapeutic use*; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007893:Leishmania donovani / Q000187:drug effects; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000469:parasitology; D008055:Lipids; D051379:Mice; D008807:Mice, Inbred BALB C; D010715:Phosphatidylglycerols / Q000737:chemistry; D011134:Polysaccharides / Q000737:chemistry
D000981:Antiprotozoal Agents; D004337:Drug Carriers; D008055:Lipids; D010715:Phosphatidylglycerols; D011134:Polysaccharides; C068538:liposomal amphotericin B; D000666:Amphotericin B; C030345:1,2-dipalmitoylphosphatidylglycerol